Institutional Ownership
Jasper Therapeutics Inc
CUSIP 471871202COM NEWJSPRQ1 2026
13D / 13G Filings
24
Schedule 13D/13G on record
Beneficial Filers
16
Distinct reporting persons
Largest Stake
11.0%
Max % of class reported
Institutional Holders
55
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
24 filings · latest Feb 25, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 25, 2026 | Integrated Core Strategies (Us) LLC | 13G | 11.0% | 1.63M | SEC |
| 2 | Feb 18, 2026 | The Carlyle Group Inc. | 13D/A | 3.8% | — | SEC |
| 3 | Feb 12, 2026 | The Goldman Sachs Group, Inc. | 13G | 11.0% | 1.76M | SEC |
| 4 | Feb 11, 2026 | Morgan Stanley | 13G | 7.0% | 1.97M | SEC |
| 5 | Jan 26, 2026 | Acorn Bioventures, L.P. | 13G/A | 5.3% | 1.49M | SEC |
| 6 | Dec 2, 2025 | Acorn Bioventures, L.P. | 13G | 6.4% | 1.79M | SEC |
| 7 | Nov 14, 2025 | T. Rowe Price Investment Management, Inc. | 13G | 7.1% | 2.06M | SEC |
| 8 | Nov 14, 2025 | Qiming U.S. Healthcare Fund II, L.P. | 13G/A | 3.3% | 929.0K | SEC |
| 9 | Nov 12, 2025 | Kingdon Capital Management, L.L.C. | 13G/A | 4.7% | 1.32M | SEC |
| 10 | Nov 7, 2025 | Morgan Stanley | 13G/A | 2.8% | 784.6K | SEC |
14 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Jasper Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Velan Capital Investment Management LP | 2.67M | $2.34M |
| 2 | Millennium Management LLC | 1.62M | $1.42M |
| 3 | Acorn Capital Advisors, LLC | 1.41M | $1.24M |
| 4 | Kingdon Capital Management, L.L.C. | 1.35M | $1.18M |
| 5 | Morgan Stanley | 1.33M | $1.17M |
| 6 | Rock Springs Capital Management LP | 1.10M | $964.5K |
| 7 | Carlyle Group Inc. | 1.07M | $934.2K |
| 8 | Boothbay Fund Management, LLC | 582.8K | $510.6K |
| 9 | Lion Point Capital, LP | 465.0K | $407.4K |
| 10 | Jacobs Levy Equity Management, Inc | 322.3K | $282.4K |